Treatment with ledipasvir and sofosbuvir improves patient‐reported outcomes: Results from the ION‐1, ‐2, and ‐3 clinical trials

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|61|6|1798-1808

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.61, Iss.6, 2015-06, pp. : 1798-1808

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens

By  

HEPATOLOGY, Vol. 61, Iss. 6, 2015-06 ,pp. : 1793-1797

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patient-Reported Outcomes, Patient-Reported Information: From Randomized Controlled Trials to the Social Web and Beyond

By Baldwin Mike  

The Patient: Patient-Centered Outcomes Research, Vol. 4, Iss. 1, 2011-01 ,pp. : 11-17

Adis International

Access to resources Recommend Favorite

Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials

By  

HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. : 25-30

John Wiley & Sons Inc

Access to resources Recommend Favorite

Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 8, 2015-08 ,pp. : 1555-1561

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of inhaled insulin on patient-reported outcomes and treatment preference in patients with type 1 diabetes

By Hayes Risa P.   Muchmore Douglas   Schmitke Jennifer  

Current Medical Research and Opinion, Vol. 23, Iss. 2, 2007-02 ,pp. : 435-442

Informa Healthcare

Access to resources Recommend Favorite